17-amino-acid synthetic peptide · Thymosin Beta-4 fragment
TB-500
Thymosin Beta-4 fragment for systemic tissue repair and cellular migration.
- Half-life~2 hours plasma half-life
- Dose range2 to 5 mg loading, twice weekly · 4 to 8 week cycle
- Reconstituted stability28 days, 2–8 °C
- VerificationCOA included
Mechanism
How it works.
Promotes cellular migration via actin-binding regulation. Supports angiogenesis and modulates inflammatory environment around healing tissue.
Research
What the research shows.
Animal studies show accelerated wound healing and cardiac tissue repair. Human-research base is preliminary. Most-studied recovery context: combined with BPC-157 for soft-tissue work.
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein involved in actin sequestration and cell migration. The proposed mechanism centres on supporting cellular migration to sites of injury, which is why the compound is studied as a complement to BPC-157 in recovery protocols.
Animal-research evidence is broader than human evidence. Veterinary use in racehorse recovery is well-documented; human-research use sits in the research-context catalogue. Subcutaneous protocol patterns lean toward larger boluses given less frequently than BPC-157.
Contraindications
When not to use.
Active malignancy (theoretical angiogenic concern). Pregnancy and lactation. No clinician oversight for peri-operative windows.
Optimal pairings
Stacks well with.
Information is educational, derived from published research. Not medical advice. All compounds sold for research use only. Bloodwork and a clinical consultation should precede any new protocol.